



Clinical Group

Journal of Surgery and Surgical Research

ISSN: 2455-2968

DOI

CC BY

Line Schjøtt Nissen¹, Jacob Hunter¹,
Henrik Daa Schrøder², Kenneth Rütz³
and Peter Bollen^{1*}

¹Biomedical Laboratory, Faculty of Health Sciences,
University of Southern Denmark

²Institute of Regional Health Services, Faculty of
Health Sciences, University of Southern Denmark

³Department of Surgery, Odense University Hospital,
Odense, Denmark

Dates: Received: 06 July, 2017; Accepted: 14 August,
2017; Published: 16 August, 2017

*Corresponding author: Peter Bollen, Head of Department,
Biomedical Laboratory, University of Southern
Denmark, Denmark, Tel: +45 65503798;
E-mail: pbollen@health.sdu.dk

Keywords: Hemostatical patch; Inflammatory
response; Animal study

<https://www.peertechz.com>

Research Article

Adhesions, inflammatory response and foreign body giant cells infiltration of the topical hemostats TachoSil[®], Hemopatch[™] and Veriset[™] – An Animal Study

Abstract

Background: When liver bleeding cannot be controlled by conventional methods, a topical hemostatic patch can be applied during surgery. In recent years new hemostats have become available. The aim of this study was to investigate the degree of adhesion and inflammation for three topical hemostatic patches, TachoSil[®], Hemopatch[™] and Veriset[™].

Methods: In 60 adult male Sprague Dawley rats liver two lesions were induced with a scalpel. Each rat was treated with two of the three patches tested. After 1, 2 and 3 months the animals were euthanized and macroscopic evaluation of adhesions and histological assessment of inflammation and macrophage infiltration were performed.

Results: A significant higher ($p < 0.05$) occurrence of foreign body giant cells (FBGCs) was found in Hemopatch[™] and Veriset[™], whereas both had a lower degree of inflammatory and macrophage infiltration compared to TachoSil[®]. No differences in the occurrence of adhesions were found.

Conclusion: Our study found evidence for difference in inflammation and formation of foreign body giant cells for the three hemostatic patches.

Introduction

Bleeding during hepatic surgery is associated with a higher risk of morbidity and mortality and cannot always be controlled by compression, ligature or other conventional procedures [1-4]. The occurrence of bleeding during liver resections and liver transplantations is minimized due to new methods of resection, such as segmented resections and proximal hemostasis [5,6]. Hemostatic sealants and topical patches are now also widely used. In Denmark, three patches are available for this purpose. TachoSil[®] (Takeda, Austria) is a topical hemostatic patch for mild or moderate bleeding based on human fibrin and thrombin on an equine collagen patch [7]. Hemopatch[™] (Baxter AG, Austria) is made from bovine collagen with reactive pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate (NHS-PEG) on the active side, which initiates the organisms own clotting mechanisms [8,9]. Veriset[™] (Covidien, USA) is a cellulose matrix with a non-specified polyethylene glycol (PEG) on the active side [10,11].

The risk of adhesions has proven to be lower by topical hemostatic patches compared to conventional methods of hemostasis [12,13]. However, biomaterials cause a foreign body response, which is the end-stage response of the inflammatory and wound healing responses, characterized by protein adsorption, macrophage adhesion and fusion of the macrophages into foreign body giant cells (FBGCs) [14]. FBGCs are found in larger numbers in adhesions, and indicative for adhesion formation [15].

The aim of our study was to compare three topical hemostatic patches with respect to occurrence of adhesion and inflammation, macrophage infiltration, and occurrence of FBGCs.

Materials and Methods

The study was designed as a randomised trial with 60 adult male Sprague Dawley rats. The rats were divided in three groups of 20 rats. Each rat received 2 patches on 2 separate

038

liver lobes. The patches were divided through randomisation with all rats receiving 2 different patches. Two standardized lesions (diameter 1 mm) were made with a scalpel after surgical exposure of the liver on separate lobes, and a patch was applied on each location. One group was euthanized 1 months after surgery, a second group after 2 months and a third group was euthanized 3 months after surgery. One rat was euthanized preliminary due to post-operative complications, and not included in the study.

The study was approved by an ethical committee (Danish Animal Experiments Inspectorate, j.nr. 2012-15-2934-00129) and performed at approved animal facilities.

Anaesthesia

The rats had a mean weight of 266 ± 19.4 grams (mean \pm SD) on the day of the operation. They were anaesthetized by SC injection of fentanyl $236 \mu\text{g}/\text{kg}$, fluanisone $7.5 \text{ mg}/\text{kg}$ and midazolam $3.75 \text{ mg}/\text{kg}$. The rat was placed on a heated operating table and an SC injection with 3 ml was given and Viscotears applied on the eyes to prevent dehydration, whereas oxygen was supplied via a nose mask.

Surgery

A 3 cm longitudinal midline incision was made from the *Proc. xiphoideus* and the abdominal wall was opened by blunt dissection. The liver lobe was held with cotton tip and a standardized lesion was made with an approximate diameter of 1 mm, ensuring to perforate the liver capsule and liver parenchyma. This always yielded a bleed, which is necessary for the patches to function. A patch measuring $20 \times 20 \text{ mm}$ was applied using the manufacturer's instructions. In most cases this was enough to ensure hemostasis, but in some of the rats, application was difficult. The patch either slipped off or did not cover the lesion. In these cases the patch was reapplied. The abdominal wall was closed with a continuous suture with 4-0 Vicryl suture (Ethicon, Belgium) and the skin was closed with 6-10 clips (Visistat® Weck skin stapler 35w, Teleflex Medical, USA).

Postoperative procedures

The rats were placed in individual cages for three days, and treated with buprinorphine (Temgesic, $40 \mu\text{g}/\text{kg}$ SC) for 72 hours postoperatively every nine hours. They had access to standard rodent chow, water and Diet Gel® (Clear H₂O, USA). Hereafter they were placed in home cages, with four rats in each cage.

Necropsy

The rats were euthanized in pairs in a CO₂ chamber which was gradually filled with oxygen 1 l/min and carbon dioxide 5 l/min. and necropsy was performed. The degree of adhesion was scored according to Zühlke et al. [16], including dissemination from liver and patch area to the abdominal wall or other organs. The liver was extracted and preserved in a formalin solution.

Histology

The livers were processed and stained with Haematoxylin Eosin and Sirius Red. The slides were scanned with a high-resolution scanner from Hamamatsu (NanoZoomer 2.0-HT C9600, Photonics, Japan), 20x magnification, and analysed using the software specific NPD-viewer (Viewing software, NDP.view2 U12388-01, Japan).

Occurrence of inflammation (plasma cells and lymphocyte infiltration) and macrophages in the inner and outer layer of the patch was scored and presence of FBGCs was graded. The occurrence of fibrosis and neovascularization was included as well. Odds Ratios (OR) were calculated using the score for TachoSil as a reference. The OR for Hemopatch and Veriset was calculated as the deviation from the score of TachoSil.

Statistical analysis

We used non-parametric statistics for binary data. The statistical analysis was performed with Stata® 13.1 (StataCorp, USA). The tests used were χ^2 , Fisher's exact test and logistic regression. All data was converted to binary data to make the data easily interpretable and presentable.

Results

The degree of adhesion, including dissemination from liver and patch area to the abdominal wall or other organs is presented in table 1. No significant differences were found.

Occurrence of inflammation (plasma cells and lymphocyte infiltration) and macrophages in the inner and outer layer of the patch was scored and presence of FBGCs was graded, and presented as Odds Ratios with TachoSil as a reference. The results are presented in tables 2,3, together with the occurrence of fibrosis and neovascularization.

No differences were found between the groups euthanized after 1, 2 or 3 months, and consequently the results from the groups were pooled. TachoSil® had significantly higher inflammation scores than Hemopatch™ and Veriset™ for both inner and outer layer. Also, TachoSil® had a significantly higher occurrence of macrophages than Hemopatch™ and Veriset™ for the inner layer, while no significance was found for outer layer. FBGCs in the inner layer were found more often in Hemopatch™ and Veriset™ than in TachoSil®. No significant differences between the patches were found for FBGCs in the outer layer.

Table 1: The degree of adhesion, including dissemination from liver and patch area to the abdominal wall or other organs.

| Adhesion score | Characteristics |
|----------------|--|
| 0 | No adhesions |
| 1 | Filmy adhesions separable by blunt dissection |
| 2 | Stronger adhesions where blunt dissection is possible or partly sharp dissection is necessary. Minimal vascularisation |
| 3 | Strong adhesions where lysis is only possible by sharp dissection. Clear vascularisation |
| 4 | Very strong adhesions where lysis is only possible by sharp dissection. Organs strongly attached with severe adhesions and damage to organs hardly preventable |

Table 2: Odds Ratio (OR) of inflammation (plasma cell and lymphocyte infiltration), macrophage infiltration and the occurrence of foreign body giant cells (FBGCs), as well as OR scores for fibrosis and neovascularisation with TachoSil as reference.

| | | Hemopatch ^a | | | Veriset ^a | | |
|-----------------------------|---------------------|------------------------|-----------------------|--------|----------------------|-----------------------|-------|
| | | OR ^b | [95% CI] ^c | | OR ^b | [95% CI] ^c | |
| Inflammation | Inner | 0.34* | 0.13 | 0.85 | 0.29* | 0.11 | 0.72 |
| | Outer | 0.27* | 0.09 | 0.76 | 0.13* | 0.04 | 0.43 |
| Macrophages | Inner | 0.25* | 0.09 | 0.69 | 0.17* | 0.06 | 0.49 |
| | Outer | 0.44 | 0.13 | 1.48 | 0.25* | 0.06 | 0.99 |
| FBGCs ^d | Inner | 0.20* | 0.07 | 0.55 | 0.32* | 0.07 | 0.86 |
| | Outer | 0.78 | 0.24 | 2.52 | 3.79 | 0.71 | 20.14 |
| Fibrosis | Inner | 0.14 | -0.14 | 0.43 | 0.14 | -0.15 | 0.42 |
| | Outer | 0.04 | -0.39 | 0.46 | -0.54* | -0.97 | -0.11 |
| Neovascularisation | Inner | 0.66 | 0.26 | 1.64 | 0.44 | 0.17 | 1.12 |
| | Outer | 2.14 | 0.80 | 5.71 | 1.61 | 0.60 | 4.32 |
| Remaining Patch | | 1.05 | 0.14 | 7.85 | 0.16* | 3.79 | 78.26 |
| Patch infiltration | | 1.04 | 0.20 | 5.50 | 0.27 | 0.07 | 1.08 |
| FBGCs ^d in patch | | 9.16* | 3.17 | 26.42 | 0.52 | 0.19 | 1.42 |
| Patch folding | Right and Left lobe | 5.92* | 1.17 | 30.04 | 1.39 | 0.00 | 0.12 |
| | Left lobe | 11.77* | 1.32 | 105.01 | 1.89 | 0.01 | 22.79 |

All data has been calculated for groups A, B and C combined.

*Significant p-value < 0.05.

^aAll results in the table are calculated with TachoSil as reference.

^bOR: Odds Ratio.

^c95% CI: 95% Confidence Interval.

^dFBGCs: Foreign Body Giant Cells.

Table 3: Number of patches divided between the 60 rats. Each rat was treated with 2 patches and divided in 3 groups which were euthanized after 1, 2 and 3 months. Each rat received one patch on their right liver lobe and one on the left liver lobe.

| | TachoSil | | Hemopatch | | Veriset | |
|---|------------|-----------|------------|-----------|------------|-----------|
| | Right Lobe | Left Lobe | Right Lobe | Left Lobe | Right Lobe | Left Lobe |
| Rats treated with the patches for 1 month | n=5 | n=8 | n=8 | n=6 | n=7 | n=6 |
| Rats treated with the patches for 2 month | n=8 | n=5 | n=5 | n=8 | n=7 | n=7 |
| Rats treated with the patches for 3 month | n=7 | n=6 | n=5 | n=7 | n=8 | n=7 |

Discussion

The pathophysiology of adhesion formation is not fully understood. It is believed that the formation of fibrin, an essential part of the coagulation cascade, acts as a scaffold for collagen deposition and neovascularisation. If the fibrin is not lysed within 5–7 days of surgery the temporary matrix persists and gradually becomes an organized peritoneal adhesion [17]. The three patches caused a similar degree of adhesion, so the different components of the patches, human fibrin and thrombin on an equine collagen in TachoSil®, NHS-PEG in Hemopatch™ and PEG in Veriset™ have no influence on adhesion formation.

According to Arung et al. [17,18], adhesion formation is the result of an inflammatory response to tissue injury. Our study did not find a positive association between markers of inflammation and the formation of adhesions, even in a patch yielding a high amount of inflammation. According to Nohuz et al. [12], TachoSil® is preventative in formation of adhesions in a rat model, where TachoSil® is tested against electrocoagulation. We could not confirm this finding, since TachoSil® caused a similar level of adhesions as Hemopatch™ and Veriset™. However, results from rat studies cannot be necessarily extrapolated to humans due to the many factors that play a role in adhesion formation [19].

Hemopatch™ and Veriset™, both patches containing PEG, caused higher presence of FBGCs than TachoSil®. Anderson et al. [14], state that particles of non-specified polyethylene from prosthesis and other biomaterials induce FBGC-formation, and explains this as the result of frustrated phagocytosis. FBGCs help degrading foreign bodies by releasing enzymes and reactive oxygen intermediates. Nagelschmidt et al. [20], showed that an intraperitoneal PEG-solution, given after a laparoscopic procedure, reduces the formation of adhesions, suggesting that PEG containing patches should cause fewer adhesions. FBGCs are found in larger numbers in adhesions, and are indicative for adhesion formation [15], so it would be expected that Hemopatch™ and Veriset™ had lower levels of FBGCs if the PEG in these patches would reduce the formation of adhesions. The FBGC-reaction to PEG, and the importance of FBGCs in adhesion formation is an interesting area for further investigation.

Acknowledgments

We thank Claire Gudex, MD, Odense University Hospital, for assistance with the text and staff at the Biomedical Laboratory of the University of Southern Denmark and technical assistance.

Funding and disclosures

This study was funded by the Department of Surgery, Odense University Hospital. The authors declare no conflict of interest.

References

- Tjandra JJ, Fan ST, Wong J (1991) Peri-operative mortality in hepatic resection. The Australian and New Zealand journal of surgery 61: 201-206. [Link: https://goo.gl/MG8NPu](https://goo.gl/MG8NPu)
- Strong RW, Lynch SV, Wall DR, Ong TH (1994) The safety of elective liver resection in a special unit. Aust N Z J Surg 64: 530-534. [Link: https://goo.gl/K2ybLU](https://goo.gl/K2ybLU)
- Bozzetti F, Gennari L, Regalia E, Bignami P, Montalto F, et al. (1992) Morbidity and mortality after surgical resection of liver tumors. Analysis of 229 cases. Hepatogastroenterology. 39: 237-241. [Link: https://goo.gl/c64qyp](https://goo.gl/c64qyp)
- Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, et al. (2004) Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg 240: 698-708. [Link: https://goo.gl/m4HyeE](https://goo.gl/m4HyeE)
- Imamura H, Seyama Y, Kokudo N, Maema A, Sugawara Y, et al. (2003) One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 138: 1198-1206. [Link: https://goo.gl/TscnVV](https://goo.gl/TscnVV)

6. Jung SW, Hwang S, Namgoong JM, Yoon SY, Park CS, et al. (2012) Incidence and management of postoperative abdominal bleeding after liver transplantation. *Transplant Proc* 44: 765-768. [Link: https://goo.gl/EuV1K2](https://goo.gl/EuV1K2)
7. Kakaei F, Seyyed Sadeghi MS, Sanei B, Hashemzadeh S, Habibzadeh A (2013) A randomized clinical trial comparing the effect of different hemostatic agents for hemostasis of the liver after hepatic resection. *HPB surgery* 2013: 587608. [Link: https://goo.gl/YmJZ7r](https://goo.gl/YmJZ7r)
8. Lewis KM, Spazierer D, Slezak P, Baumgartner B, Regenbogen J, et al. (2014) Swelling, sealing, and hemostatic ability of a novel biomaterial: A polyethylene glycol-coated collagen pad. *J Biomater Appl* 29: 780-788. [Link: https://goo.gl/jsiinR](https://goo.gl/jsiinR)
9. Lewis KM, Schiviz A, Hedrich HC, Regenbogen J, Goppelt A (2014) Hemostatic efficacy of a novel, PEG-coated collagen pad in clinically relevant animal models. *Int J Surg* 12: 940-944. [Link: https://goo.gl/hcCr2S](https://goo.gl/hcCr2S)
10. Ollinger R, Mihaljevic AL, Schuhmacher C, Bektas H, Vondran F, et al. (2013) A multicentre, randomized clinical trial comparing the Veriset hemostatic patch with fibrin sealant for the management of bleeding during hepatic surgery. *HPB surgery* 15: 548-558. [Link: https://goo.gl/3YbYDH](https://goo.gl/3YbYDH)
11. Nohuz E, Darcha C, Moreno W, Tamburro S, Yanez M, et al. (2009) Efficiency of TachoSil to prevent postsurgical adhesion development on laparoscopic rat model. *Gynecological Surgery* 6: 323-329. [Link: https://goo.gl/tWR9Nb](https://goo.gl/tWR9Nb)
12. Kuschel TJ, Gruszka A, Hermanns-Sachweh B, Elyakoubi J, Sachweh JS, et al. (2013) Prevention of postoperative pericardial adhesions with TachoSil. *Ann Thorac Surg* 95: 183-188. [Link: https://goo.gl/muujSX](https://goo.gl/muujSX)
13. Anderson JM, Rodriguez A, Chang DT (2008) Foreign body reaction to biomaterials. *Seminars in immunology* 20: 86-100. [Link: https://goo.gl/kghwPT](https://goo.gl/kghwPT)
14. Duron JJ (2007) Postoperative intraperitoneal adhesion pathophysiology. *Colorectal disease* 9 Suppl 2: 14-24. [Link: https://goo.gl/hPgBvr](https://goo.gl/hPgBvr)
15. Zuhlke HV, Lorenz EM, Straub EM, Savvas V (1990) Pathophysiology and classification of adhesions. *Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir.* 1990: 1009-1016. [Link: https://goo.gl/pcH3qZ](https://goo.gl/pcH3qZ)
16. Arung W, Meurisse M, Detry O (2011) Pathophysiology and prevention of postoperative peritoneal adhesions. *World J Gastroenterol* 17: 4545-4553. [Link: https://goo.gl/E2iwsU](https://goo.gl/E2iwsU)
17. Milligan DW, Raftery AT (1974) Observations on the pathogenesis of peritoneal adhesions: a light and electron microscopical study. *The British journal of surgery* 61: 274-280. [Link: https://goo.gl/1CxMQ7](https://goo.gl/1CxMQ7)
18. Bischoff SC (2007) Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. *Nature reviews Immunology* 7: 93-104. [Link: https://goo.gl/fPx9bY](https://goo.gl/fPx9bY)
19. Nagelschmidt M, Minor T, Saad S (1998) Polyethylene glycol 4000 attenuates adhesion formation in rats by suppression of peritoneal inflammation and collagen incorporation. *Am J Surg* 176: 76-80. [Link: https://goo.gl/Aaa4GZ](https://goo.gl/Aaa4GZ)
20. Baxter (2017) How HEMOPATCH Works [Internet]: Baxter International INC; [accessed March 2017]. [Link: https://goo.gl/B242iE](https://goo.gl/B242iE)